Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia.

Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang JY, Lai YJ, Lin CW, Chen HY, Liu FT, Chou WC, Chen CY, Tang JL, Yao M, Huang SY, Ko BS, Wu SJ, Tsay W, Tien HF.

Blood. 2013 Apr 18;121(16):3172-80. doi: 10.1182/blood-2012-07-443762. Epub 2013 Feb 28.

2.

Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.

Chen YK, Hou HA, Tang JL, Jhuang JY, Lai YJ, Lee MC, Kuo YY, Chou WC, Liu CY, Lin CW, Chuang SS, Chen CY, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

PLoS One. 2015 Mar 20;10(3):e0119831. doi: 10.1371/journal.pone.0119831. eCollection 2015.

3.

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF.

Blood. 2011 Oct 6;118(14):3803-10. doi: 10.1182/blood-2011-02-339747. Epub 2011 Aug 9.

4.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

PMID:
20439648
5.

Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.

Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Jan;44(1):55-61. doi: 10.1016/j.humpath.2012.04.008. Epub 2012 Aug 28.

PMID:
22939316
6.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
7.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

8.

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Blood. 2012 Jan 12;119(2):559-68. doi: 10.1182/blood-2011-07-369934. Epub 2011 Nov 10.

9.

Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.

de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM, van der Weide K, de Bont ES, Huls G, Vellenga E, Schuringa JJ.

Leukemia. 2011 Dec;25(12):1825-33. doi: 10.1038/leu.2011.172. Epub 2011 Jul 15.

PMID:
21760593
10.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M.

J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.

PMID:
21670448
11.

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Blood. 2010 Jun 24;115(25):5222-31. doi: 10.1182/blood-2009-12-259390. Epub 2010 Apr 5.

12.

Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.

Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H.

Eur J Haematol. 2004 Feb;72(2):89-106.

PMID:
14962246
13.

Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.

Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.

Ann Hematol. 2007 Oct;86(10):741-7. Epub 2007 Jun 20.

PMID:
17579862
14.

Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.

Zhang TJ, Wu DH, Zhou JD, Li XX, Zhang W, Guo H, Ma JC, Deng ZQ, Lin J, Qian J.

J Cell Physiol. 2018 Apr;233(4):3274-3281. doi: 10.1002/jcp.26171. Epub 2017 Sep 28.

PMID:
28884855
15.

FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.

Ghosh K, Swaminathan S, Madkaikar M, Gupta M, Kerketta L, Vundinti B.

Ann Hematol. 2012 Nov;91(11):1703-12. doi: 10.1007/s00277-012-1509-z. Epub 2012 Jun 26.

PMID:
22733614
16.

[Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].

Wang YG, Liu XH, Liang Y, Jin J.

Zhonghua Xue Ye Xue Za Zhi. 2008 Nov;29(11):741-5. Chinese.

PMID:
19176010
17.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C.

Cancer. 2009 Aug 15;115(16):3719-27. doi: 10.1002/cncr.24442.

18.

Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.

Gao N, Yu WZ, Guo NJ, Wang XX, Sun JR.

Leuk Lymphoma. 2017 Jun;58(6):1394-1402. doi: 10.1080/10428194.2016.1243677. Epub 2016 Oct 13.

PMID:
27736291
19.

High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.

Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Schmetzer H.

Am J Hematol. 2005 May;79(1):26-35.

20.

Detailed analysis of FLT3 expression levels in acute myeloid leukemia.

Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S.

Haematologica. 2005 Dec;90(12):1617-25.

Supplemental Content

Support Center